MYJETVA Trademark

Trademark Overview

On Thursday, April 28, 2022, a trademark application was filed for MYJETVA with the United States Patent and Trademark Office. The USPTO has given the MYJETVA trademark a serial number of 97386777. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, November 19, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The MYJETVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and skin disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

General Information

Serial Number97386777
Word MarkMYJETVA
Filing DateThursday, April 28, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, November 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 28, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and skin disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 3, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Thursday, February 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 2, 2022NEW APPLICATION ENTERED
Tuesday, May 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 2, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, February 7, 2023ASSIGNED TO EXAMINER
Wednesday, February 15, 2023NON-FINAL ACTION WRITTEN
Wednesday, February 15, 2023NON-FINAL ACTION E-MAILED
Wednesday, February 15, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 21, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, February 21, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, February 21, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, February 21, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, February 21, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 28, 2023PUBLISHED FOR OPPOSITION
Tuesday, March 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 23, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, November 24, 2023SOU EXTENSION 1 FILED
Monday, December 25, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, December 26, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Thursday, January 4, 2024TEAS PETITION TO REVIVE RECEIVED
Thursday, January 4, 2024PETITION TO REVIVE-GRANTED
Thursday, January 4, 2024NOTICE OF REVIVAL - E-MAILED
Thursday, January 4, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Thursday, January 4, 2024NOTICE OF REVIVAL - E-MAILED
Wednesday, February 14, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 16, 2024SOU EXTENSION 1 GRANTED
Monday, May 6, 2024SOU EXTENSION 2 GRANTED
Monday, May 6, 2024SOU EXTENSION 2 FILED
Monday, May 6, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, February 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 19, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, November 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 19, 2024SOU EXTENSION 3 FILED
Tuesday, November 19, 2024SOU EXTENSION 3 GRANTED

Related Keywords

myjetva disorders diseases preparations pharmaceutical treatment fertility hormone replacement dependence infectious